1. Home
  2. EBF vs DSGN Comparison

EBF vs DSGN Comparison

Compare EBF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ennis Inc.

EBF

Ennis Inc.

HOLD

Current Price

$18.28

Market Cap

467.2M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.92

Market Cap

504.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBF
DSGN
Founded
1909
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
467.2M
504.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EBF
DSGN
Price
$18.28
$9.92
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
234.5K
442.6K
Earning Date
12-22-2025
11-05-2025
Dividend Yield
5.53%
N/A
EPS Growth
4.41
N/A
EPS
1.66
N/A
Revenue
$388,740,000.00
N/A
Revenue This Year
$0.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.30
$2.60
52 Week High
$22.01
$10.31

Technical Indicators

Market Signals
Indicator
EBF
DSGN
Relative Strength Index (RSI) 59.17 62.56
Support Level $17.89 $8.43
Resistance Level $18.47 $9.68
Average True Range (ATR) 0.42 0.71
MACD 0.03 -0.07
Stochastic Oscillator 52.31 82.35

Price Performance

Historical Comparison
EBF
DSGN

About EBF Ennis Inc.

Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: